Should we continue to target the platelet-activating factor pathway in septic patients?

Critical Care Medicine

Volumn 32, Issue 2, 2004, Pages 585-588

  Minneci, Peter C ^b   Deans, Katherine J ^b   Banks, Steven M ^a   Eichacker, Peter Q ^a   Natanson, Charles ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Mediator specific anti inflammatory agents; Platelet activating factor; Platelet activating factor acetylhydrolase; Platelet activating factor receptor antagonist; Sepsis; Septic shock

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACTIVATED PROTEIN C; RECOMBINANT PROTEIN; THROMBOCYTE ACTIVATING FACTOR;

CLINICAL TRIAL; DRUG RESEARCH; EDITORIAL; HUMAN; INTENSIVE CARE; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPSIS; SURVIVAL RATE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APACHE; HUMANS; SEPSIS; SURVIVAL RATE;

EID: 1242297506     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000110730.38696.9C     Document Type: Editorial

References (38)

1. Opal SM, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for the treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32:332-341
2. Schuster DP, Metzler M, Opal S, et al: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-1619
3. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22:1720-1728
4. Dhainaut JF, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26: 1963-1971
5. Poeze M, Froon AH, Ramsay G, et al: Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: A prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 2000; 14:421-428
6. Vincent JL, Spapen H, Bakker J, et al: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28:638-642
7. Froon AM, Greve JW, Buurman WA, et al: Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: A prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5:313-319
8. Heuer HO: Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids 1991; 26:1369-1373
9. Prescott SM, McIntyre TM, Zimmerman G: Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury. J Clin Invest 1999; 104: 1019-1020
10. Henson PM, Barnes PJ, Banks-Schlegel SP: NHLBI workshop summary: Platelet-activating factor: Role in pulmonary injury and dysfunction and blood abnormalities. Am Rev Respir Dis 1992; 145:726-731
11. Sorensen J, Kald B, Tagesson C, et al: Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med 1994; 20:555-561
12. Siebeck M, Weipert J, Keser C, et al: A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991; 31:942-949; discussion 949-950
13. Olson NC, Joyce PB, and Fleisher LN: Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs. Am J Physiol 1990; 258:H1674-H1686
14. Christman BW, Lefferts PL, Blair IA, et al: Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1990; 142:1272-1278
15. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
16. Abraham E, Glauser MP, Butler T, et al: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-1538
17. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933
18. Abraham E, Laterre PF, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-510
19. Bernard GR, Reines HD, Halushka PV, et al: Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome: Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991; 144:1095-1101
20. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918
21. Clark MA, Plank LD, Connolly AB, et al: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: A randomized, clinical trial. Crit Care Med 1998; 26:1650-1659
22. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
23. Dhainaut JF, Vincent JL, Richard C, et al: CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469
24. Fein AM, Bernard GR, Criner GJ, et al: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277:482-487
25. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-327
26. Fisher CJ Jr, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22:12-21
27. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
28. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
29. Haupt MT, Jastremski MS, Clemmer TP, et al: Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 1991; 19:1339-1347
30. Kay C: Paper presented at Cambridge Health Institute's Designing Better Drugs and Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers. Washington, DC, 1996
31. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-1124
32. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742
33. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
34. Rodell TC, Scharschmidt LA, Knaus WA: CP-0127 SIRS and Sepsis Study Group: Results of a multi-center randomized, placebo-controlled trial of CP-0127, a novel bradykinin antagonist, in patients with SIRS and sepsis. Shock 1995; 3:60
35. Natanson C, Esposito C, Banks SM: The siren's songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931
36. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
37. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
38. Knaus WA, Harrell FE Jr, LaBrecque JF, et al: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24:46-56